Thursday, August 03, 2017 8:56:51 AM
MATN - .3777
Press Release: Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Recent Corporate Highlights
-- Granted Fast Track designation by U.S. Food and Drug Administration for
OXi4503 for treatment of acute myeloid leukemia (AML);
-- Announced two complete remissions (50%) in the fifth cohort of the
OXi4503 study for the treatment of relapsed/refractory AML;
-- Completed enrollment of the FOCUS study of CA4P for the treatment of
platinum-resistant ovarian cancer;
-- Announced positive data for CA4P in combination with immune-oncology
agents demonstrating significant reduction in tumor size in an animal
model.
"With renewed interest in the clinical potential of our vascular disrupting agents, our programs have picked up significant momentum and have advanced ahead of schedule," said William D. Schwieterman , M.D., President and Chief Executive Officer. "We recently observed new evidence of efficacy in our AML study, as well as completed enrollment in the first part of the FOCUS study. I am pleased we have advanced our programs to important data inflection points. We all look forward to further advancing this important therapeutic class."
Press Release: Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Recent Corporate Highlights
-- Granted Fast Track designation by U.S. Food and Drug Administration for
OXi4503 for treatment of acute myeloid leukemia (AML);
-- Announced two complete remissions (50%) in the fifth cohort of the
OXi4503 study for the treatment of relapsed/refractory AML;
-- Completed enrollment of the FOCUS study of CA4P for the treatment of
platinum-resistant ovarian cancer;
-- Announced positive data for CA4P in combination with immune-oncology
agents demonstrating significant reduction in tumor size in an animal
model.
"With renewed interest in the clinical potential of our vascular disrupting agents, our programs have picked up significant momentum and have advanced ahead of schedule," said William D. Schwieterman , M.D., President and Chief Executive Officer. "We recently observed new evidence of efficacy in our AML study, as well as completed enrollment in the first part of the FOCUS study. I am pleased we have advanced our programs to important data inflection points. We all look forward to further advancing this important therapeutic class."
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
